Jim Barrett, PhD, joined NEA, an investment company, in 2001 as a general partner. He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Mr. Barrett’s present board memberships include Cardioxyl Pharmaceuticals, GlycoMimetics, Inc., Inhibitex, Inc. (INHX), Nucleonics, Inc., Peptimmune, Inc., Predictive Biosciences, Proteostasis Therapeutics, Inc., Psyadon Pharmaceuticals, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (TRGT), and Zosano Pharma, Inc. Mr. Barrett formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), lomai Corporation (acquired by Intercell A G), Medlmmune, Inc. (acquired by AstraZeneca) and Pharmion (acquired by Celgene). Prior to NEA, Mr. Barrett founded and served as chairman / CEO of Sensors for Medicine and Science (1997-2001), where he remains chairman. Prior to 1997, he led three NEA-funded companies, serving as chairman / CEO of Genetic Therapy, Inc. (1987-1995), president / CEO of Life Technologies (1985-1987), and president / CEO of Bethesda Research Labs (1982-1983). Prior to 1982, Mr. Barrett worked in various divisions of SmithKline. He holds a PhD in biochemistry from the University of Tennessee, an MBA from University of Santa Clara, and a BS in chemistry from Boston College.


print email
Price Data
NASDAQROKA